Follistatin

Follistatin is an endogenous glycoprotein encoded by the FST gene and best characterized as a high-affinity binding protein for activins, with additional interactions across the TGF-beta superfamily. It was originally described in reproductive endocrinology, where it modulates follicle-stimulating hormone biology through activin neutralization, but later research places it in broader tissue repair, inflammation, fibrosis, metabolism, and skeletal-muscle signaling. The safest framing is mechanistic: follistatin regulates ligand availability rather than acting like a simple growth-promoting peptide. Therapeutic claims in humans remain narrow and experimental, especially for gene-therapy approaches aimed at muscle disease.

Activin Binding and Reproductive Biology

Follistatin's most established research role is binding and neutralizing activins, which helps regulate reproductive endocrine signaling and local tissue responses ^[1][2].

Inflammation and Muscle Research

The activin-follistatin axis is studied in inflammation, immunity, and muscle biology, including experimental gene-therapy contexts ^[3][4].

Evidence Boundary

General follistatin elevation or supplementation is not established as safe or effective for performance, fertility, anti-aging, or body-composition goals ^[1][4].

Broad Pathway Biology

Follistatin is a regulatory protein, not a dietary nutrient or approved general-use therapy. Broad activin blockade may affect reproductive, immune, inflammatory, and tissue-remodeling pathways ^[1][2][3].

Cancer and Growth-Signaling Caution

Cancer literature describes context-dependent associations between follistatin signaling and tumor biology, so simplistic growth or repair claims are not appropriate ^[5].